PMID: 15217557Jun 26, 2004Paper

The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications

Current Hematology Reports
Elizabeth M Kang, John F Tisdale

Abstract

Hematopoietic stem cell gene transfer using integrating vectors has been actively investigated for more than two decades as a prospective treatment for several congenital and acquired human diseases, and retroviral vectors encoding potentially therapeutic genes have been the most rigorously pursued. Early trials in humans testing retroviral vectors in several clinical settings supported the safety of this approach, and recent studies have demonstrated remarkable efficacy in children with severe combined immunodeficiency. The anticipated success established the therapeutic potential of hematopoietic stem cell gene transfer, but the subsequent development of leukemia in two treated children has re-emphasized the risks related to gene therapy. In this review, we describe this complication, discuss the leukemogenic risk of integrating retroviral vectors, and propose strategies to decrease the likelihood of its occurrence.

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Molecular Therapy : the Journal of the American Society of Gene Therapy
C BaumDavid A Williams
Pediatric Blood & Cancer
Nikolaos V KarathanasisMaria Kalmanti
Chinese Medical Journal
Chao-Hua Deng, Qiu-Ping Zhang
Molecular Therapy : the Journal of the American Society of Gene Therapy
Karin Pike-OverzetFrank J T Staal
© 2022 Meta ULC. All rights reserved